Novo Nordisk AS (NVO)
105.32
-1.59
(-1.49%)
USD |
NYSE |
Nov 14, 16:00
105.06
-0.26
(-0.25%)
After-Hours: 20:00
Novo Nordisk Cash and Short Term Investments (Quarterly): 11.22B for Sept. 30, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 11.22B |
| June 30, 2024 | 8.994B |
| March 31, 2024 | 1.346B |
| December 31, 2023 | 4.488B |
| September 30, 2023 | 6.741B |
| June 30, 2023 | 5.313B |
| March 31, 2023 | 4.065B |
| December 31, 2022 | 3.393B |
| September 30, 2022 | 4.953B |
| June 30, 2022 | 4.358B |
| March 31, 2022 | 3.023B |
| December 31, 2021 | 2.662B |
| September 30, 2021 | 5.521B |
| June 30, 2021 | 4.355B |
| March 31, 2021 | 1.208B |
| December 31, 2020 | 2.109B |
| September 30, 2020 | 4.018B |
| June 30, 2020 | 3.752B |
| March 31, 2020 | 1.442B |
| December 31, 2019 | 2.320B |
| September 30, 2019 | 2.749B |
| June 30, 2019 | 2.202B |
| March 31, 2019 | 1.361B |
| December 31, 2018 | 2.396B |
| September 30, 2018 | 2.552B |
| Date | Value |
|---|---|
| June 30, 2018 | 2.853B |
| March 31, 2018 | 1.738B |
| December 31, 2017 | 3.038B |
| September 30, 2017 | 3.029B |
| June 30, 2017 | 3.281B |
| March 31, 2017 | 2.552B |
| December 31, 2016 | 2.944B |
| September 30, 2016 | 2.495B |
| June 30, 2016 | 2.276B |
| March 31, 2016 | 1.346B |
| December 31, 2015 | 2.998B |
| September 30, 2015 | 2.641B |
| June 30, 2015 | 1.780B |
| March 31, 2015 | 1.042B |
| December 31, 2014 | 2.597B |
| September 30, 2014 | 2.322B |
| June 30, 2014 | 1.193B |
| March 31, 2014 | 951.58M |
| December 31, 2013 | 2.678B |
| September 30, 2013 | 2.439B |
| June 30, 2013 | 1.944B |
| March 31, 2013 | 1.929B |
| December 31, 2012 | 2.854B |
| September 30, 2012 | 3.038B |
| June 30, 2012 | 2.074B |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
1.208B
Minimum
Mar 2021
11.22B
Maximum
Sep 2024
4.264B
Average
4.041B
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Ascendis Pharma AS | 277.30M |
| Amgen Inc | 9.011B |
| AstraZeneca PLC | 7.076B |
| Grifols SA | 901.05M |
| Viking Therapeutics Inc | 930.44M |